Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.46 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.45 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3023896 | 0.82 | MAPT (0.49) | MAPTTP53MAPK1GAAALOX15 | |
| SCHEMBL7446579 | 0.80 | MAPK1 (0.48) | MAPTTP53MAPK1GAAALOX15 | |
| SCHEMBL7353383 | 0.75 | LMNA (0.49) | MAPTTP53MAPK1GAAALOX15 | |
| SCHEMBL7165819 | 0.75 | MAPT (0.63) | MAPTTP53MAPK1GAAALOX15 | |
| SCHEMBL7160571 | 0.75 | MAPT (0.55) | MAPTTP53MAPK1GAAALOX15 | |
| SCHEMBL4140802 | 0.73 | KMT2A (0.56) | MAPTTP53MAPK1GAAMEN1 | |
| SCHEMBL3018829 | 0.73 | MEN1 (0.53) | MAPTTP53MAPK1GAAALOX15 | |
| SCHEMBL7347313 | 0.73 | NR3C1 (0.45) | MAPTTP53GAAMEN1KMT2A | |
| SCHEMBL7167114 | 0.71 | MAPT (0.60) | MAPTTP53MAPK1GAAALOX15 | |
| SCHEMBL988 | 0.70 | MAPT (0.50) | MAPTTP53MAPK1GAAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461165-B2 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD (CN) | 2013-06-11 | — | — | US | disclosed |
| US-8461165-B2 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD (CN) | 2013-06-11 | — | — | US | disclosed |
| EP-1634883-B1 | 2-SUBSTITUTED PHENYL-5,7-DIALKYL-3,7-DIHYDROPYRROLE[2,3-D] PYRIMIDINE-4-ONE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL G (CN) | 2010-12-15 | — | — | EP | disclosed |
| US-20100204223-A1 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2010-08-12 | — | — | US | disclosed |
| US-20100204223-A1 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2010-08-12 | — | — | US | disclosed |
| US-7745433-B2 | 2-Substituted phenyl-5, 7-dihydrocarbyl-3, 7-dihydropyrrolo [2, 3-D] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | Yangtze River Pharmacuetical (Group) Co., Ltd. (CN) | 2010-06-29 | — | — | US | disclosed |
| US-7745433-B2 | 2-Substituted phenyl-5, 7-dihydrocarbyl-3, 7-dihydropyrrolo [2, 3-D] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | Yangtze River Pharmacuetical (Group) Co., Ltd. (CN) | 2010-06-29 | — | — | US | disclosed |
| US-7741483-B2 | Process for making substituted pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of phosphodiesterase 5 | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2010-06-22 | — | — | US | disclosed |
| US-7741483-B2 | Process for making substituted pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of phosphodiesterase 5 | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2010-06-22 | — | — | US | disclosed |
| US-20080167462-A1 | 2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | TIANJIN TASLY GROUP CO., LTD (CN) | 2008-07-10 | — | — | US | disclosed |
| US-20080167462-A1 | 2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | TIANJIN TASLY GROUP CO., LTD (CN) | 2008-07-10 | — | — | US | disclosed |
| US-20060173025-A1 | 2-Substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole [2,3-d]pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2006-08-03 | — | — | US | disclosed |
| EP-1634883-A1 | 2-SUBSTITUTED PHENYL-5,7-DIALKYL-3,7-DIHYDROPYRROLE[2,3-D]PYRIMIDINE-4-ONE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | Tianjin Tasly Group Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167462-A1 | 2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | PDE5A, PDE3B, PDE2A | MAPT 4551/4885TP53 4809/4885MAPK1 2081/4885 |
| US-20060173025-A1 | 2-Substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole [2,3-d]pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof | PDE5A, PDE3B, PDE2A | MAPT 4606/4885TP53 4748/4885MAPK1 2763/4885 |
| US-20100204223-A1 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | PDE5A, PDE3A, PDE2A | MAPT 4286/4885TP53 4820/4885MAPK1 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.